Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
T1h (Itolizumab) Phase 1 in Chinese Psoriasis Patients
NCT02649270Phase 1Terminated
- Start
- Oct 2014
- Primary completion
- Jun 2015
- Modality
- Monoclonal Antibodies
- Countries
- 1
01
Overview
Phase 1, open-label trial of itolizumab in psoriasis (4 arms). Primary endpoint: Adverse events. Started Oct 2014; status: terminated.
02
Drugs
itolizumab
03
Conditions
psoriasis
Beyond the preview
Go deeper on NCT02649270.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02649270.